Geron Corporation's product was approved in the United States and the company was listed on Nasdaq on August 19, 2025.
7 reports, 3 independent
Updated Fri 00:00
Mostly repetition
- Reports
- 7
- Developments
- 3
- Repetition
- 71%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Geron Corporation's product was approved in the United States and the company was listed on Nasdaq on August 19, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Geron Corporation is advancing its telomerase pipeline toward commercial availability.1 source
- Geron Corporation's product received regulatory approval in the European Union on June 1, 2026.Sub-event
Geron Corporation receives US product approval and lists on Nasdaq.1 source
Keep exploring
The entities involved
-
Geron Corporation
company
Nothing else this week.
Coverage
Newest first; wire copies grouped- bubblear.com
- yahoo.com
- Business WireGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FOSTER CITY, Calif., August 18, 2025--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmac
- Business WireGeron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025 FOSTER CITY, Calif., July 28, 2025--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceut
- Business WireGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FOSTER CITY, Calif., July 18, 2025--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceu